Emerging advances in cationic liposomal cancer nanovaccines: opportunities and challenges

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. World Health Organization. Cancer. (2020). www.who.int/news-room/fact-sheets/detail/cancer
  Google Scholar
• 2. American Cancer Society. Cancer Facts & Figures 2019. (2019). www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2019/cancer-facts-and-figures-2019.pdf
  Google Scholar
• 3. Howard CJ, Charleston B, Stephens SA, Sopp P, Hope JC. The role of dendritic cells in shaping the immune response. Anim. Health. Res. Rev. 5(2), 191–195 (2004).
  Medline CASGoogle Scholar
• 4. Gao A, Hu XL, Saeed M, Chen BF, Li YP, Yu HJ. Overview of recent advances in liposomal nanoparticle-based cancer immunotherapy. Acta. Pharmacol. Sin. 40(9), 1129–1137 (2019).
  Medline CASGoogle Scholar
• 5. Mbongue J, Nicholas D, Firek A, Langridge W. The role of dendritic cells in tissue-specific autoimmunity. J. Immunol. Res. 2014, 857143–857143 (2014).
  MedlineGoogle Scholar
• 6. Nesmiyanov P. British Society for Immunology. Antigen Processing and Presentation. (2020). www.immunology.org/public-information/bitesized-immunology/systems-and-processes/antigen-processing-and-presentation
  Google Scholar
• 7. Jia J, Zhang Y, Xin Y, Jiang C, Yan B, Zhai S. Interactions between nanoparticles and dendritic cells: from the perspective of cancer immunotherapy. Front. Oncol. 8, 404 (2018). • Recent progress in targeting dendritic cells using nanoparticles as a drug-delivery carrier in cancer immunotherapy.
  MedlineGoogle Scholar
• 8. Ahmad MZ, Ahmad J, Haque A, Alasmary M, Abdel-Wahab B, Akhter S. Emerging advances in synthetic cancer nano-vaccines: opportunities and challenges. Expert Rev. Vaccines 19(11), 1053–1071 (2020). •• Advancements in nanomedicine-based cancer nanovaccines.
  Medline CASGoogle Scholar
• 9. Grimaldi AM, Incoronato M, Salvatore M, Soricelli A. Nanoparticle-based strategies for cancer immunotherapy and immunodiagnostics. Nanomedicine (Lond.) 12(19), 2349–2365 (2017).
  CASGoogle Scholar
• 10. Liu J, Zhang R, Xu ZP. Nanoparticle-based nanomedicines to promote cancer immunotherapy: recent advances and future directions. Small 15(32), e1900262 (2019).
  MedlineGoogle Scholar
• 11. Yan S, Zhao P, Yu T, Gu N. Current applications and future prospects of nanotechnology in cancer immunotherapy. Cancer Biol. Med. 16(3), 486–497 (2019).
  Medline CASGoogle Scholar
• 12. Van Der Burg SH, Arens R, Ossendorp F, Van Hall T, Melief CJ. Vaccines for established cancer: overcoming the challenges posed by immune evasion. Nat. Rev. Cancer 16(4), 219–233 (2016).
  MedlineGoogle Scholar
• 13. Schwendener RA. Liposomes as vaccine delivery systems: a review of the recent advances. Ther. Adv. Vaccines 2(6), 159–182 (2014).
  Medline CASGoogle Scholar
• 14. Blume G, Cevc G, Crommelin MD, Bakker-Woudenberg IA, Kluft C, Storm G. Specific targeting with poly(ethylene glycol)-modified liposomes: coupling of homing devices to the ends of the polymeric chains combines effective target binding with long circulation times. Biochem. Biophys. Acta. 1149(1), 180–184 (1993).
  Medline CASGoogle Scholar
• 15. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug. Discov. 4(2), 145–160 (2005).
  Medline CASGoogle Scholar
• 16. Watson DS, Endsley AN, Huang L. Design considerations for liposomal vaccines: influence of formulation parameters on antibody and cell-mediated immune responses to liposome associated antigens. Vaccine 30(13), 2256–2272 (2012). •• Rational design of liposomal vaccines to elicit immune responses of a desired magnitude and quality.
  Medline CASGoogle Scholar
• 17. Henriksen-Lacey M, Devitt A, Perrie Y. The vesicle size of DDA:TDB liposomal adjuvants plays a role in the cell-mediated immune response but has no significant effect on antibody production. J. Control Rel. 154(2), 131–137 (2011).
  Medline CASGoogle Scholar
• 18. Evelyn Roopngam P. Liposome and polymer-based nanomaterials for vaccine applications. Nanomed. J. 6(1), 1–10 (2019).
  Google Scholar
• 19. Shenzhen Institutes of Advanced Technology. CN102973506A (2011).
  Google Scholar
• 20. National Taiwan Ocean University (NTOU). US20110182976A1 (2011).
  Google Scholar
• 21. PDS Biotechnology Corporation. CN102137675A (2009).
  Google Scholar
• 22. Inex Pharmaceuticals Corporation. JP2005530761A (2003).
  Google Scholar
• 23. Curevac AG. ES2759910T3 (2020).
  Google Scholar
• 24. Allison AC, Gregoriadis G. Liposomes as immunological adjuvants. In: Lymphocytes, Macrophages, and Cancer. Mathe GFlorentin ISimmler M-C (Eds). Springer Berlin Heidelberg, Berlin, Heidelberg, Germany, 58–64 (1976).
  Google Scholar
• 25. Allison AG, Gregoriadis G. Liposomes as immunological adjuvants. Nature 252(5480), 252 (1974).
  Medline CASGoogle Scholar
• 26. Shao K, Singha S, Clemente-Casares X, Tsai S, Yang Y, Santamaria P. Nanoparticle-based immunotherapy for cancer. ACS Nano. 9(1), 16–30 (2015).
  Medline CASGoogle Scholar
• 27. Mahjub R, Jatana S, Lee SE et al. Recent advances in applying nanotechnologies for cancer immunotherapy. J. Control. Rel. 288, 239–263 (2018). •• Advancement in nanotechnology for immunotherapy against cancer.
  Medline CASGoogle Scholar
• 28. Kwong B, Gai SA, Elkhader J, Wittrup KD, Irvine DJ. Localized immunotherapy via liposome-anchored anti-CD137 + IL-2 prevents lethal toxicity and elicits local and systemic antitumor immunity. Cancer Res. 73(5), 1547 (2013).
  Medline CASGoogle Scholar
• 29. Pardoll DM. Paracrine cytokine adjuvants in cancer immunotherapy. Annu. Rev. Immunol. 13(1), 399–415 (1995).
  Medline CASGoogle Scholar
• 30. Chen WC, Huang L. Non-viral vector as vaccine carrier. Adv. Genet. 54, 315–337 (2005).
  Medline CASGoogle Scholar
• 31. Zamani P, Momtazi-Borojeni AA, Nik ME, Oskuee RK, Sahebkar A. Nanoliposomes as the adjuvant delivery systems in cancer immunotherapy. J. Cell. Physiol. 233(7), 5189–5199 (2018). • Properties of nanoliposomes as delivery systems for cancer immunotherapy.
  Medline CASGoogle Scholar
• 32. Liang MT, Davies NM, Toth I. Encapsulation of lipopeptides within liposomes: effect of number of lipid chains, chain length and method of liposome preparation. Int. J. Pharm. 301(1–2), 247–254 (2005).
  Medline CASGoogle Scholar
• 33. Dancey GF, Yasuda T, Kinsky SC. Effect of liposomal model membrane composition on immunogenicity. J. Immunol. 120(4), 1109–1113 (1978).
  Medline CASGoogle Scholar
• 34. Nakano Y, Mori M, Nishinohara S et al. Surface-linked liposomal antigen induces ige-selective unresponsiveness regardless of the lipid components of liposomes. Bioconjug. Chem. 12(3), 391–395 (2001).
  Medline CASGoogle Scholar
• 35. Mazumdar T, Anam K, Ali N. Influence of phospholipid composition on the adjuvanticity and protective efficacy of liposome-encapsulated Leishmania donovani antigens. J. Parasitol. 91(2), 269–274 (2005).
  Medline CASGoogle Scholar
• 36. Christensen D, Henriksen-Lacey M, Kamath AT et al. A cationic vaccine adjuvant based on a saturated quaternary ammonium lipid have different in vivo distribution kinetics and display a distinct CD4 T cell-inducing capacity compared to its unsaturated analog. J. Control. Rel. 160(3), 468–476 (2012).
  Medline CASGoogle Scholar
• 37. Badiee A, Khamesipour A, Samiei A et al. The role of liposome size on the type of immune response induced in BALB/c mice against leishmaniasis: rgp63 as a model antigen. Exp. Parasitol. 132(4), 403–409 (2012).
  Medline CASGoogle Scholar
• 38. Bachmann MF, Jennings GT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol. 10(11), 787–796 (2010).
  Medline CASGoogle Scholar
• 39. Reddy ST, Van Der Vlies AJ, Simeoni E et al. Exploiting lymphatic transport and complement activation in nanoparticle vaccines. Nat. Biotechnol. 25(10), 1159–1164 (2007).
  Medline CASGoogle Scholar
• 40. Carstens MG, Camps MG, Henriksen-Lacey M et al. Effect of vesicle size on tissue localization and immunogenicity of liposomal DNA vaccines. Vaccine 29(29–30), 4761–4770 (2011).
  Medline CASGoogle Scholar
• 41. Manolova V, Flace A, Bauer M, Schwarz K, Saudan P, Bachmann MF. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol. 38(5), 1404–1413 (2008).
  Medline CASGoogle Scholar
• 42. Kaminskas LM, Porter CJ. Targeting the lymphatics using dendritic polymers (dendrimers). Adv. Drug Deliv. Rev. 63(10–11), 890–900 (2011).
  Medline CASGoogle Scholar
• 43. Kourtis IC, Hirosue S, De Titta A et al. Peripherally administered nanoparticles target monocytic myeloid cells, secondary lymphoid organs and tumors in mice. PLoS ONE 8(4), e61646 (2013).
  Medline CASGoogle Scholar
• 44. Brewer JM, Tetley L, Richmond J, Liew FY, Alexander J. Lipid vesicle size determines the Th1 or Th2 response to entrapped antigen. J. Immunol. 161(8), 4000–4007 (1998). • Novel mechanism by which the balance of the Th1/Th2 response to an Ag can be influenced.
  Medline CASGoogle Scholar
• 45. Oyewumi MO, Kumar A, Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev. Vaccines 9(9), 1095–1107 (2010).
  Medline CASGoogle Scholar
• 46. Conniot J, Silva JM, Fernandes JG et al. Cancer immunotherapy: nanodelivery approaches for immune cell targeting and tracking. Front. Chem. 2, 105 (2014). • Nanodelivery strategies for cancer immunotherapy, cancer targeting mechanisms and nanocarrier functionalization.
  MedlineGoogle Scholar
• 47. Perrie Y, Crofts F, Devitt A, Griffiths HR, Kastner E, Nadella V. Designing liposomal adjuvants for the next generation of vaccines. Adv. Drug Deliv. Rev. 99(Pt A), 85–96 (2016).
  Medline CASGoogle Scholar
• 48. Wang N, Chen M, Wang T. Liposomes used as a vaccine adjuvant-delivery system: from basics to clinical immunization. J. Control. Rel. 303, 130–150 (2019).
  Medline CASGoogle Scholar
• 49. Foged C, Arigita C, Sundblad A, Jiskoot W, Storm G, Frokjaer S. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine 22(15–16), 1903–1913 (2004).
  Medline CASGoogle Scholar
• 50. Werninghaus K, Babiak A, Gross O et al. Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcRgamma-Syk-Card9-dependent innate immune activation. J. Exp. Med. 206(1), 89–97 (2009).
  Medline CASGoogle Scholar
• 51. Henriksen-Lacey M, Christensen D, Bramwell VW et al. Liposomal cationic charge and antigen adsorption are important properties for the efficient deposition of antigen at the injection site and ability of the vaccine to induce a CMI response. J. Control. Rel. 145(2), 102–108 (2010).
  Medline CASGoogle Scholar
• 52. Norris DA, Puri N, Sinko PJ. The effect of physical barriers and properties on the oral absorption of particulates. Adv. Drug Deliv. Rev. 34(2–3), 135–154 (1998).
  Medline CASGoogle Scholar
• 53. Schmidt ST, Khadke S, Korsholm KS et al. The administration route is decisive for the ability of the vaccine adjuvant CAF09 to induce antigen-specific CD8(+) T-cell responses: the immunological consequences of the biodistribution profile. J. Control. Rel. 239, 107–117 (2016).
  Medline CASGoogle Scholar
• 54. Wang T, Zhen Y, Ma X, Wei B, Li S, Wang N. Mannosylated and lipid A-incorporating cationic liposomes constituting microneedle arrays as an effective oral mucosal HBV vaccine applicable in the controlled temperature chain. Colloids Surf. B. Biointerfaces 126, 520–530 (2015).
  Medline CASGoogle Scholar
• 55. Yuba E. Liposome-based immunity-inducing systems for cancer immunotherapy. Mol. Immunol. 98, 8–12 (2018).
  Medline CASGoogle Scholar
• 56. Heuts J, Varypataki EM, Van Der Maaden K et al. Cationic liposomes: a flexible vaccine delivery system for physicochemically diverse antigenic peptides. Pharm. Res. 35(11), 207 (2018).
  MedlineGoogle Scholar
• 57. Vanbever R, Loira-Pastoriza C, Dauguet N et al. Cationic nanoliposomes are efficiently taken up by alveolar macrophages but have little access to dendritic cells and interstitial macrophages in the normal and CpG-stimulated lungs. Mol. Pharm. 16(5), 2048–2059 (2019).
  Medline CASGoogle Scholar
• 58. Yan W, Chen W, Huang L. Mechanism of adjuvant activity of cationic liposome: phosphorylation of a MAP kinase, ERK and induction of chemokines. Mol. Immunol. 44(15), 3672–3681 (2007). •• Adjuvant properties of cationic liposome.
  Medline CASGoogle Scholar
• 59. Chen W, Huang L. Induction of cytotoxic T-lymphocytes and antitumor activity by a liposomal lipopeptide vaccine. Mol. Pharm. 5(3), 464–471 (2008).
  Medline CASGoogle Scholar
• 60. Chen W, Yan W, Huang L. A simple but effective cancer vaccine consisting of an antigen and a cationic lipid. Cancer Immunol. Immunother. 57(4), 517–530 (2008).
  Medline CASGoogle Scholar
• 61. Yan W, Chen W, Huang L. Reactive oxygen species play a central role in the activity of cationic liposome based cancer vaccine. J. Control. Rel. 130(1), 22–28 (2008). •• Role of reactive oxygen species in the activity of cationic liposome.
  Medline CASGoogle Scholar
• 62. Yan W, Huang L. The effects of salt on the physicochemical properties and immunogenicity of protein based vaccine formulated in cationic liposome. Int. J. Pharm. 368(1–2), 56–62 (2009).
  Medline CASGoogle Scholar
• 63. Yun CH, Bae CS, Ahn T. Cargo-free nanoparticles containing cationic lipids induce reactive oxygen species and cell death in HepG2 cells. Biol. Pharm. Bull. 39(8), 1338–1346 (2016).
  Medline CASGoogle Scholar
• 64. Wang C, Zhuang Y, Zhang Y et al. Toll-like receptor 3 agonist complexed with cationic liposome augments vaccine-elicited antitumor immunity by enhancing TLR3-IRF3 signaling and type I interferons in dendritic cells. Vaccine 30(32), 4790–4799 (2012).
  Medline CASGoogle Scholar
• 65. Alipour Talesh G, Ebrahimi Z, Badiee A et al. Poly (I:C)-DOTAP cationic nanoliposome containing multi-epitope HER2-derived peptide promotes vaccine-elicited anti-tumor immunity in a murine model. Immunol. Lett. 176, 57–64 (2016).
  MedlineGoogle Scholar
• 66. Zhuang Y, Ma Y, Wang C et al. PEGylated cationic liposomes robustly augment vaccine-induced immune responses: role of lymphatic trafficking and biodistribution. J. Control. Rel. 159(1), 135–142 (2012). •• Functionalized cationic lipsome and enhanced immune response.
  Medline CASGoogle Scholar
• 67. Zhang J, Tian H, Li C et al. Antitumor effects obtained by autologous Lewis lung cancer cell vaccine engineered to secrete mouse interleukin 27 by means of cationic liposome. Mol. Immunol. 55(3–4), 264–274 (2013).
  Medline CASGoogle Scholar
• 68. Mansourian M, Badiee A, Jalali SA et al. Effective induction of anti-tumor immunity using p5 HER-2/neu derived peptide encapsulated in fusogenic DOTAP cationic liposomes co-administrated with CpG-ODN. Immunol. Lett. 162(1 Pt A), 87–93 (2014).
  Medline CASGoogle Scholar
• 69. Yazdani M, Hatamipour M, Alani B et al. Liposomal gp100 vaccine combined with CpG ODN sensitizes established B16F10 melanoma tumors to anti PD-1 therapy Iran. J. Basic Med. Sci. 23(8), 1065–1077 (2020).
  MedlineGoogle Scholar
• 70. Varypataki EM, Van Der Maaden K, Bouwstra J, Ossendorp F, Jiskoot W. Cationic liposomes loaded with a synthetic long peptide and poly(I:C): a defined adjuvanted vaccine for induction of antigen-specific T cell cytotoxicity. Aaps. J. 17(1), 216–226 (2015).
  Medline CASGoogle Scholar
• 71. Sayour EJ, De Leon G, Pham C et al. Systemic activation of antigen-presenting cells via RNA-loaded nanoparticles. Oncoimmunology 6(1), e1256527 (2017).
  MedlineGoogle Scholar
• 72. Shen KY, Liu HY, Li HJ et al. A novel liposomal recombinant lipoimmunogen enhances anti-tumor immunity. J. Control. Rel. 233, 57–63 (2016).
  Medline CASGoogle Scholar
• 73. Barati N, Nikpoor AR, Razazan A et al. Nanoliposomes carrying HER2/neu-derived peptide AE36 with CpG-ODN exhibit therapeutic and prophylactic activities in a mice TUBO model of breast cancer. Immunol. Lett. 190, 108–117 (2017).
  Medline CASGoogle Scholar
• 74. Liu C, Chu X, Sun P et al. Synergy effects of Polyinosinic-polycytidylic acid, CpG oligodeoxynucleotide, and cationic peptides to adjuvant HPV E7 epitope vaccine through preventive and therapeutic immunization in a TC-1 grafted mouse model. Hum. Vaccin. Immunother. 14(4), 931–940 (2018).
  MedlineGoogle Scholar
• 75. Siegel DP, Epand RM. The mechanism of lamellar-to-inverted hexagonal phase transitions in phosphatidylethanolamine: implications for membrane fusion mechanisms. Biophys. J. 73(6), 3089–3111 (1997).
  Medline CASGoogle Scholar
• 76. Kunisawa J, Mayumi T. [Application of novel drug delivery system, fusogenic liposome, for cancer therapy. Gan. To. Kagaku. Ryoho. 28(5), 577–583 (2001). • Fusogenic liposome in cancer therapy.
  Medline CASGoogle Scholar
• 77. Kunisawa J, Nakagawa S, Mayumi T. Pharmacotherapy by intracellular delivery of drugs using fusogenic liposomes: application to vaccine development. Adv. Drug Deliv. Rev. 52(3), 177–186 (2001).
  Medline CASGoogle Scholar
• 78. Okazaki S, Iwasaki T, Yuba E, Watarai S. Evaluation of pH-sensitive fusogenic polymer-modified liposomes co-loaded with antigen and α-galactosylceramide as an anti-tumor vaccine. J. Vet. Med. Sci. 80(2), 197–204 (2018).
  Medline CASGoogle Scholar
• 79. Razazan A, Behravan J, Arab A et al. Conjugated nanoliposome with the HER2/neu-derived peptide GP2 as an effective vaccine against breast cancer in mice xenograft model. PLoS ONE 12(10), e0185099 (2017).
  MedlineGoogle Scholar
• 80. Farzad N, Barati N, Momtazi-Borojeni AA et al. P435 HER2/neu-derived peptide conjugated to liposomes containing DOPE as an effective prophylactic vaccine formulation for breast cancer. Artif. Cells Nanomed. Biotechnol. 47(1), 665–673 (2019).
  MedlineGoogle Scholar
• 81. Persano S, Guevara ML, Li Z et al. Lipopolyplex potentiates anti-tumor immunity of mRNA-based vaccination. Biomaterials 125, 81–89 (2017).
  Medline CASGoogle Scholar
• 82. Arab A, Behravan J, Razazan A et al. A nano-liposome vaccine carrying E75, a HER-2/neu-derived peptide, exhibits significant antitumour activity in mice. J. Drug Target. 26(4), 365–372 (2018). •• Significant anticancer activity of nanoliposome loaded with HER-2/neu-derived peptide.
  Medline CASGoogle Scholar
• 83. Shariat S, Badiee A, Jalali SA et al. P5 HER2/neu-derived peptide conjugated to liposomes containing MPL adjuvant as an effective prophylactic vaccine formulation for breast cancer. Cancer Lett. 355(1), 54–60 (2014).
  Medline CASGoogle Scholar
• 84. Zamani P, Navashenaq JG, Nikpoor AR et al. MPL nano-liposomal vaccine containing P5 HER2/neu-derived peptide pulsed PADRE as an effective vaccine in a mice TUBO model of breast cancer. J. Control. Rel. 303, 223–236 (2019).
  Medline CASGoogle Scholar
• 85. Vitor MT, Bergami-Santos PC, Zômpero RHF et al. Cationic liposomes produced via ethanol injection method for dendritic cell therapy. J. Liposome Res. 27(4), 249–263 (2017).
  Medline CASGoogle Scholar
• 86. Lechanteur A, Furst T, Evrard B, Delvenne P, Hubert P, Piel G. Development of anti-E6 pegylated lipoplexes for mucosal application in the context of cervical preneoplastic lesions. Int. J. Pharm. 483(1–2), 268–277 (2015).
  Medline CASGoogle Scholar
• 87. Simberg D, Weisman S, Talmon Y, Barenholz Y. DOTAP (and other cationic lipids): chemistry, biophysics, and transfection. Crit. Rev. Ther. Drug Carrier Syst. 21(4), 257–317 (2004).
  Medline CASGoogle Scholar
• 88. Porteous DJ, Dorin JR, Mclachlan G et al. Evidence for safety and efficacy of DOTAP cationic liposome mediated CFTR gene transfer to the nasal epithelium of patients with cystic fibrosis. Gene Ther. 4(3), 210–218 (1997).
  Medline CASGoogle Scholar
• 89. Fasol U, Frost A, Büchert M et al. Vascular and pharmacokinetic effects of EndoTAG-1 in patients with advanced cancer and liver metastasis. Ann. Oncol. 23(4), 1030–1036 (2012).
  Medline CASGoogle Scholar
• 90. Strieth S, Dunau C, Michaelis U et al. Phase I/II clinical study on safety and antivascular effects of paclitaxel encapsulated in cationic liposomes for targeted therapy in advanced head and neck cancer. Head Neck 36(7), 976–984 (2014).
  MedlineGoogle Scholar
• 91. Ignatiadis M, Zardavas D, Lemort M et al. Feasibility study of EndoTAG-1, a tumor endothelial targeting agent, in combination with paclitaxel followed by FEC as induction therapy in HER2-negative breast cancer. PLoS ONE 11(7), e0154009 (2016).
  MedlineGoogle Scholar
• 92. Awada A, Bondarenko IN, Bonneterre J et al. A randomized controlled Phase II trial of a novel composition of paclitaxel embedded into neutral and cationic lipids targeting tumor endothelial cells in advanced triple-negative breast cancer (TNBC). Ann. Oncol. 25(4), 824–831 (2014).
  Medline CASGoogle Scholar
• 93. ClinicalTrials.gov, National Library of Medicine (U.S.). EndoTAG-1 plus gemcitabine versus gemcitabine alone in patients with measurable locally advanced and/or metastatic adenocarcinoma of the pancreas failed on FOLFIRINOX treatment NCT03126435. (2017). https://clinicaltrials.gov/ct2/show/NCT03126435
  Google Scholar
• 94. Cho EA, Moloney FJ, Cai H et al. Safety and tolerability of an intratumorally injected DNAzyme, Dz13, in patients with nodular basal-cell carcinoma: a Phase I first-in-human trial (DISCOVER). Lancet 381(9880), 1835–1843 (2013).
  Medline CASGoogle Scholar
• 95. Lu C, Stewart DJ, Lee JJ et al. Phase I clinical trial of systemically administered TUSC2(FUS1)-nanoparticles mediating functional gene transfer in humans. PLoS ONE 7(4), e34833 (2012).
  Medline CASGoogle Scholar
• 96. ClinicalTrials.gov, National Library of Medicine (U.S.). TUSC2-nanoparticles and erlotinib in stage IV lung cancer NCT01455389. (2011). https://clinicaltrials.gov/ct2/show/NCT01455389
  Google Scholar
• 97. Zhi D, Zhang S, Wang B, Zhao Y, Yang B, Yu S. Transfection efficiency of cationic lipids with different hydrophobic domains in gene delivery. Bioconjug. Chem. 21(4), 563–577 (2010).
  Medline CASGoogle Scholar
• 98. Sayour EJ, Mendez-Gomez HR, Mitchell DA. Cancer vaccine immunotherapy with RNA-loaded liposomes. Int. J. Mol. Sci. 19(10), 2890 (2018).
  Google Scholar